Amicus Therapeutics (FOLD) – Press Releases
-
WuXi Biologics Reports Solid 2023 Annual Results
-
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
-
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
-
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
-
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
-
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
-
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
-
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
-
Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
-
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
-
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
-
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
-
Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
-
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
-
WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease
-
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
-
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
-
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
-
WuXi Biologics Reports Solid 2023 Interim Results
-
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
-
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
-
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
-
Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023
-
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
-
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
-
Amicus Therapeutics to Present at the Bank of America 2023 Health Care Conference
-
Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023
-
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
-
WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
-
Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
-
Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
-
Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
-
Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
-
Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023
-
Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023
-
Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
-
Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
-
Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
-
Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
-
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
-
Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
-
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
-
Amicus Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
-
Amicus Therapeutics Announces Participation at World Muscle Society 2022
-
Amicus Therapeutics Announces Participation at the 2022 AANEM Annual Meeting
-
Amicus Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
-
Amicus Therapeutics Announces Second Quarter 2022 Financial Results
-
Amicus Therapeutics to Announce Second Quarter 2022 Financial Results on August 4, 2022
Back to FOLD Stock Lookup
